Can-Fite Biopharma Net Income

The latest net income for CANF is $-9.8M as of December 2025. That compares with $-7.9M in the prior-year period — down 24.7% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside Can-Fite Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, CANF's net income moved from $-7.9M to $-9.8M — a 24.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Can-Fite Biopharma's operating scale or balance-sheet position.

Against Healthcare companies, CANF currently prints $-9.8M for net income, while the sector average sits near $16B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Can-Fite Biopharma's growth, margins, and balance sheet.

A net income figure of $-9.8M for CANF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting CANF's net income ($-9.8M), review year-over-year change from $-7.9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.